Winship Cancer Institute of Emory University

Winship Cancer Institute NCI Designated Cancer Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Winship Cancer Institute of Emory University is Georgia's first and only cancer center designated by the National Cancer Institute (NCI). Designation requires meeting rigorous criteria for the depth and breadth of basic science and clinical research, in addition to cancer prevention, control, and population/behavioral sciences. Designation requires effective collaboration among various disciplines and with community partners in private practice and in academic centers throughout Georgia and across the nation. With this recognition comes the responsibility to provide public information, education and outreach to other health care professionals and the community. NCI designation for Winship gives Georgians improved access to clinical trials and resources that may not be available elsewhere.

The Winship Cancer Institute (Winship) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Winship is dedicated to the integration of innovative clinical and basic science research with outstanding patient care for the prevention, treatment and control of cancer.

1-888-946-7447
winshipcancer.emory.edu

Treatment Sites in Georgia

Primary Location

1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-1900 (p)
winshipcancer.emory.edu

driving directions

Doctors:

Nazmi Volkan Adsay MD
Michael R. Aho MD
Olatunji B. Alese MD
Ana Antun MD
Cletus A. Arciero MD
Martha L. Arellano MD
Bruce J. Barron MD
Deborah A. Baumgarten MD, MPH
Jonathan J. Beitler MD, MBA, FACR
Leon Bernal MD
George G. A. Birdsong MD
Daniel J. Brat MD, PhD
Otis W. Brawley MD
Grant W. Carlson MD
Bradley C. Carthon, MD, PhD
Amy Y. Chen MD
Cynthia Cohen MD
Jonathon B Cohen MD, MS
Michael A. Cohen MD, FACR
Laronna S Colbert MD
Ian R. Crocker MD, FACR
Walter J Curran, Jr. MD, FACR
Keith A. Delman MD, FACS
Roberto R. Diaz MD
Scott H. Edelman MD
John William Eley MD, MPH
Bassel F El-Rayes MD
Christopher R. Flowers MD
Sheryl A. Gabram-Mendola MD, MBA, FACS
Manila Gaddh , MD
Anthony Andrew Gal MD
Jacques Galipeau MD
Karen D. Godette MD
Keerthi Gogineni MD
Bruce D Goldsweig MD
William J. Grist MD
Kathleen Gundry MD
Raghuveer K. Halkar MD
Chunhai Hao MD, PhD
Wayne B. Harris MD
R. Donald Harvey , PharmD
Natalyn N. Hawk MD
Leonard T. Heffner Jr., MD
Bruce W. Hershatter MD
Kristin Higgins MD
Charles E. Hill MD
Chad A. Holder MD
Stephen B. Hunter MD
Sol Jacobs MD
Ashesh B. Jani MD
David L. Jaye MD
Anand P. Jillella MD
Jonathan L. Kaufman MD
H. Jean Khoury MD, FACP
Kevin Kim MD
Adam M. Klein MD
David A. Kooby MD
Vamsi K. Kota MD
Joan Kramer
Omer Kucuk MD
J. David Lambeth MD, PhD
Jerome C. Landry MD
Amelia A. Langston MD
Stephen K. Lau MD
David H. Lawson MD
Mary Jo Lechowicz MD
Daniel J. Lee MD
Melinda Moore Lewis MD
Shiyong Li MD, PhD
James V. Little MD
Sagar Lonial MD
Shishir K. Maithel MD
Karen P. Mann MD, PhD
Viraj Master MD, PhD
Morgan L. McLemore MD
Jane L Meisel MD
Daniel L. Miller MD
David Monson MD
Melvin Moore MD
Mario Mosunjac MD
Susan C. Muller DMD, MS
Padma C. Nadella MD
Mary S. Newell MD
Peter T. Nieh MD
Ajay K. Nooka MD, MPH
Kenneth Ogan MD
Joel A Okoli MD MPH
Jeffrey J. Olson MD
Gabriela M. Oprea MD
Adeboye O. Osunkoya MD, FCAP
Taofeek K. Owonikoko MD
Nelson M. Oyesiku MD, PhD, FACS
Douglas C. Parker MD
Allan Pickens MD
Rathi Pillai MD
Suresh S. Ramalingam MD
William Read , MD
Satyanarayan K. Reddy MD
Maria J. Ribeiro MD
Monica Rizzo MD
Steven M. Roser DMD, MD
Peter J. Rossi MD
Nabil F. Saba MD, FACP
Manu S Sancheti
Juan M. Sarmiento MD
David M. Schuster MD
Judy H. Sequeira MD
Charles W. Sewell MD
Jyotirmay Sharma MD
Dong Moon Shin MD
Hui-Kuo G. Shu MD, PhD
Mark Shumate MD, MPH
Gabriel L. Sica MD
Momin T. Siddiqui MD, FIAC
William C. Small MD
Cyril O. Spann MD,SM, FACOG, FACS
Charles A. Staley MD
Liza J. Stapleford MD
Sidney F. Stein MD
Conor F Steuer
Toncred M. Styblo MD
Pakkala Suchita
Talaat S. Tadros MD
Mylin A. Torres MD
William E. Torres MD
Vijay Alluri Varma MD
Alfredo D. Voloschin MD
J. Trad Wadsworth MD
Edmund K. Waller MD, PhD, FACP
Carl Washington MD
Sharon W. Weiss MD
Ifor R. Williams MD, PhD
Elliott F. Winton MD
David Yu MD
Melinda L Yushak

Clinical Trials in Georgia

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type: Multiple Primaries
Study Coordinator: Heather Renfroe - 404-778-5127


A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma
Study Coordinator: Cathy Sharp - 404-778-3811


A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life
Cancer Type: Quality of Life
Study Coordinator: Heather Renfroe - 404-778-5127


A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101)
Cancer Type: Leukemia
Study Coordinator: Heather Johnson - 404-778-5127


A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Cancer Type: Breast Cancer, Eye Cancer, Non-Hodgkin Lymphoma, Oral Cancer, Unknown Primary

A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics (PK) and Safety of Pomalidomide (POM) When Given in Combination With Low Dose Dexamethasone (LD-DEX) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Impaired Renal Function
Cancer Type: Multiple Myeloma

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Cancer Type: Breast Cancer

A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Cancer Type: Unknown Primary

A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients With Advanced Solid Tumors
Cancer Type: Unknown Primary

A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type: Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Cancer Type: Oral Cancer

A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Cancer Type: Hodgkin Lymphoma, Leukemia, Non-Hodgkin Lymphoma

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Cancer Type: Lung Cancer

A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
Cancer Type: Hodgkin Lymphoma, Leukemia, Lymphoma, Non-Hodgkin Lymphoma

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.
Cancer Type: Kidney Cancer, Lung Cancer, Melanoma

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
Cancer Type: Leukemia

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
Cancer Type: Colon/Rectal Cancer

A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Cancer Type: Breast Cancer, Unknown Primary

A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer
Cancer Type: Cervical Cancer

A Phase 2 Study of Durvalumab and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Cancer Type: Colon/Rectal Cancer, Lung Cancer

A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cancer Type: Prostate Cancer

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Cancer Type: Eye Cancer, Leukemia

A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Cancer Type: Leukemia

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Cancer Type: Kidney Cancer

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic or Locally Advanced Unresectable Breast Cancer Gene (BRCA)-Associated Breast Cancer
Cancer Type: Breast Cancer

A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Cancer Type: Multiple Primaries
Study Coordinator: Julia Maloney - 404-778-1805


A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Cancer Type: Head and Neck Cancer, Oral Cancer

A Phase I Study With an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients with Relapsed Non-Hodgkin and Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma

A Phase Ib Clinical Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Cancer Type: Prostate Cancer

A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)
Cancer Type: Multiple Myeloma

A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Cancer Type: Liver Cancer

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158
Cancer Type: Breast Cancer

A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Cancer Type: Breast Cancer

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Cancer Type: Eye Cancer

A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Cancer Type: Skin Cancer (Non-Melanoma)

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery
Cancer Type: Breast Cancer

A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Cancer Type: Cervical Cancer
Study Coordinator: Giesla Rodgers - 404-778-5162


A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Cancer Type: Kidney Cancer

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Cancer Type: Breast Cancer

A Pilot Study of Hypofractionated Simultaneous Integrated Boost Radiotherapy in Stage 0-IIIB Breast Cancer Patients
Cancer Type: Breast Cancer

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Cancer Type: Liver Cancer

A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer
Cancer Type: Prostate Cancer

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Cancer Type: Prostate Cancer

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients With Hormone Receptor-Positive Advanced Breast Cancer
Cancer Type: Breast Cancer

A Randomized, Double Blinded Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs. Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)
Cancer Type: Breast Cancer

A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Cancer Type: Multiple Myeloma

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Cancer Type: Breast Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy
Cancer Type: Prostate Cancer
Study Coordinator: Jessica Humani - 404-778-5720


Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC
Cancer Type: Unknown Primary
Study Coordinator: Jessica Humani - 404-778-5720


An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer
Study Coordinator: Jessica Humani - 404-778-5720


An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Cancer Type: Head and Neck Cancer, Oral Cancer

An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50X10 9/L to 100 X 10 9L
Cancer Type: Symptom Management
Study Coordinator: Wilena Session - 404-778-5319


An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Cancer Type: Brain Cancer , Skin Cancer (Non-Melanoma), Unknown Primary

Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic NSCLC
Cancer Type: Lung Cancer

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer

Dose Escalation Trial of Fractionated Stereotactic Radiosurgery for Brain Metastasis Greater Than 3cm
Cancer Type: Unknown Primary
Study Coordinator: Giesla Rodgers - 404-778-5162


Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Cancer Type: Breast Cancer

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors with High Inflammation
Cancer Type: Breast Cancer

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Cancer Type: Myelodysplastic Syndromes (MDS)

Fatigue in Breast Cancer Patients Undergoing Radiotherapy; Racial Disparities in Radiotherapy Induced Skin Toxicity and Fatigue in Breast Cancer Patients; Fatigue in Breast Cancer Patients during and after Treatment; Epigenetic Memory of Chemotherapy-Induced Inflammation and Fatigue in Patients with Breast Cancer; Epigenetic Memory of Breast Cancer Treatment-Induced Inflammation and Fatigue
Cancer Type: Breast Cancer

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax-AXL-ADC) in Patients With Solid Tumors
Cancer Type: Unknown Primary

Initial Evaluation of Anti-1-amino-F-18 Flurocyclobutane-1carboxylic Acid (Anti-18F-FACBC) in the Assessment of Head and Neck Cancer: A Pilot Study.
Cancer Type: Oral Cancer

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Cancer Type: Breast Cancer

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Cancer Type: Leukemia
Study Coordinator: Heather Renfroe - 404-778-5127


Meriva for Treatment-Induced Inflammation and Fatigue in Women with Breast Cancer
Cancer Type: Breast Cancer

Omacetaxine for Consolidation and Maintenance in Patients Age 60 and Older With AML in First Remission: a Pilot Study
Cancer Type: Leukemia

Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
Cancer Type: Leukemia

Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Cancer Type: Multiple Myeloma

Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
Cancer Type: Kidney Cancer

Phase I Chemoprevention Study With Green Tea and Erlotinib in Patients With Premalignant Lesions of the Head and Neck
Cancer Type: Head and Neck Cancer
Study Coordinator: Rachel Moreno-Williams - 404-778-4147


Phase I Study of Whole Brain Radiation Therapy With Simultaneous Boost to Gross Metastatic Tumor Volume Using RapidArc
Cancer Type: Metastases
Study Coordinator: Doshia James - 404-778-5311


Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN
Cancer Type: Head and Neck Cancer, Oral Cancer

Phase Ib Trial of Pembrolizumab and XL888 in Patients with Advanced Gastrointestinal Malignancies
Cancer Type: Colon/Rectal Cancer

Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Cancer Type: Head and Neck Cancer

Phase II Study of Adjuvant Conformal Radiotherapy in High Risk Bladder Cancer
Cancer Type: Bladder Cancer

Phase II Study of Selective Bladder-Preserving Radiotherapy and Concurrent Radiosensitizing Chemotherapy in Patients With Stage I Bladder Cancer
Cancer Type: Bladder Cancer
Study Coordinator: Giesla Rodgers - 404-778-5162


Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Cancer Type: Non-Hodgkin Lymphoma

Phase II Trial of the PD-1 Antibody Nivolumab in Combination with Lenalidomide and Low Dose Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
Cancer Type: Multiple Myeloma

Phase II/III Randomized Study of Image-Guided Radiosurgery or Stereotactic Body Radiotherapy in Patients With Localized Spine Metastasis
Cancer Type: Metastases
Study Coordinator: Doshia James - 404-778-5311


Phase III Intergroup Study of Temozolomide Alone Versus Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma
Cancer Type: Brain Cancer

Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck
Cancer Type: Head and Neck Cancer
Study Coordinator: Dosha James - 404-778-5311


Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Giesla Rodgers - 404-778-5162


Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Regina Mosley - 404-778-4824


Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Cancer Type: Lung Cancer
Study Coordinator: Walter Jones


Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer

PK Button Vaporization Electrode for Treatment of Bladder Tumors
Cancer Type: Bladder Cancer
Study Coordinator: Elizabeth Ringer - 404-778-4162


Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer (Spore)
Cancer Type: Breast Cancer
Study Coordinator: Stephanie McMillan - 404-686-1855


Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Cancer Type: Kidney Cancer

Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CS3FR
Cancer Type: Myelodysplastic Syndromes (MDS)

Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Vorinostat Therapy in Newly-Diagnosed Glioblastoma (GBM) Patients
Cancer Type: Brain Cancer

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Cancer Type: Head and Neck Cancer

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Cancer Type: Oral Cancer

Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Cancer Type: Liver Cancer

Randomized Phase III Trial Of Cisplatin-Based Chemotherapy (CRT) +/- Nivolumab (Anti-PD-1) In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (With Lead In Component)
Cancer Type: Oral Cancer

Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies.
Cancer Type: Unknown Primary

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Cancer Type: Myelodysplastic Syndromes (MDS)
Study Coordinator: Wilena Session - 404-778-5319


Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer Related Pain
Cancer Type: Unknown Primary

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Cancer Type: Myelodysplastic Syndromes (MDS)
Study Coordinator: Wilena Sessions - 404-778-5319


Targeted Fusion Biopsy of the Prostate
Cancer Type: Prostate Cancer

T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis
Cancer Type: Bone and Soft Tissue (including Sarcoma)

TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Cancer Type: Head and Neck Cancer

Validation of FACBC as an Early Indicator of Sub-clinical Metastatic Disease among High-Risk Prostate Cancer Patients with Presumed Localized Disease
Cancer Type: Prostate Cancer

WCI1999-11: A Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas
Cancer Type: Brain Cancer
Study Coordinator: Kasia Kopcewicz - 404-778-2981


Winship2299-12: A Phase II Study of Subcutaneous Bevacizumab in Relapsed /Progressive Glioblastoma
Cancer Type: Brain Cancer